Innocoll appoints Anthony Wild to board
This article was originally published in Scrip
Innocoll has appointed Anthony Wild, co-founder and general partner of the Swiss drug delivery firm BOWS Pharmaceuticals, to its board of directors. Dr Wild is a member of the boards of directors of several privately-owned pharmaceutical companies and chairs the board of advisors for Ferrer, Freeman and Co, a healthcare private equity firm. He is also on the board of Celtic Therapeutics and is an advisor to Golden Pond Healthcare. He previously served as chairman of MedPointe Pharmaceuticals, where he also served as CEO from 2001 until 2006, until MedPointe was acquired by Meda in 2007.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.